The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?

The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?

Parenteral amphotericin B has been considered as first-line therapy in the treatment of systemic fungal and parasitic infections, however its use has been associated with a number of limitations including affordability, accessibility, and an array of systemic toxicities. Until very recently, it has...

Full description

Bibliographic Details
Main Authors: Grace Cuddihy, Ellen K. Wasan, Yunyun Di, Kishor M. Wasan
Format: Article
Language:English
Published: MDPI AG 2019-02-01
Series:Pharmaceutics
Subjects:
oral formulation
amphotericin B
fungal infections
parasitic infections
developing world
drug delivery
Online Access:https://www.mdpi.com/1999-4923/11/3/99
id doaj-4e4f8ad2ebc94a75added05b89ee13c4
record_format Article
spelling doaj-4e4f8ad2ebc94a75added05b89ee13c42020-11-25T00:59:50ZengMDPI AGPharmaceutics1999-49232019-02-011139910.3390/pharmaceutics11030099pharmaceutics11030099The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?Grace Cuddihy0Ellen K. Wasan1Yunyun Di2Kishor M. Wasan3College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK S7N 2Z4, CanadaCollege of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK S7N 2Z4, CanadaCollege of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK S7N 2Z4, CanadaCollege of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK S7N 2Z4, CanadaParenteral amphotericin B has been considered as first-line therapy in the treatment of systemic fungal and parasitic infections, however its use has been associated with a number of limitations including affordability, accessibility, and an array of systemic toxicities. Until very recently, it has been very challenging to develop a bioavailable formulation of amphotericin B due to its physical chemical properties, limited water and lipid solubility, and poor absorption. This perspective reviews several novel oral Amphotericin B formulations under development that are attempting to overcome these limitations.https://www.mdpi.com/1999-4923/11/3/99oral formulationamphotericin Bfungal infectionsparasitic infectionsdeveloping worlddrug delivery
collection DOAJ
language English
format Article
sources DOAJ
author Grace Cuddihy
Ellen K. Wasan
Yunyun Di
Kishor M. Wasan
spellingShingle Grace Cuddihy
Ellen K. Wasan
Yunyun Di
Kishor M. Wasan
The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?
Pharmaceutics
oral formulation
amphotericin B
fungal infections
parasitic infections
developing world
drug delivery
author_facet Grace Cuddihy
Ellen K. Wasan
Yunyun Di
Kishor M. Wasan
author_sort Grace Cuddihy
title The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?
title_short The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?
title_full The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?
title_fullStr The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?
title_full_unstemmed The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?
title_sort development of oral amphotericin b to treat systemic fungal and parasitic infections: has the myth been finally realized?
publisher MDPI AG
series Pharmaceutics
issn 1999-4923
publishDate 2019-02-01
description Parenteral amphotericin B has been considered as first-line therapy in the treatment of systemic fungal and parasitic infections, however its use has been associated with a number of limitations including affordability, accessibility, and an array of systemic toxicities. Until very recently, it has been very challenging to develop a bioavailable formulation of amphotericin B due to its physical chemical properties, limited water and lipid solubility, and poor absorption. This perspective reviews several novel oral Amphotericin B formulations under development that are attempting to overcome these limitations.
topic oral formulation
amphotericin B
fungal infections
parasitic infections
developing world
drug delivery
url https://www.mdpi.com/1999-4923/11/3/99
work_keys_str_mv AT gracecuddihy thedevelopmentoforalamphotericinbtotreatsystemicfungalandparasiticinfectionshasthemythbeenfinallyrealized
AT ellenkwasan thedevelopmentoforalamphotericinbtotreatsystemicfungalandparasiticinfectionshasthemythbeenfinallyrealized
AT yunyundi thedevelopmentoforalamphotericinbtotreatsystemicfungalandparasiticinfectionshasthemythbeenfinallyrealized
AT kishormwasan thedevelopmentoforalamphotericinbtotreatsystemicfungalandparasiticinfectionshasthemythbeenfinallyrealized
AT gracecuddihy developmentoforalamphotericinbtotreatsystemicfungalandparasiticinfectionshasthemythbeenfinallyrealized
AT ellenkwasan developmentoforalamphotericinbtotreatsystemicfungalandparasiticinfectionshasthemythbeenfinallyrealized
AT yunyundi developmentoforalamphotericinbtotreatsystemicfungalandparasiticinfectionshasthemythbeenfinallyrealized
AT kishormwasan developmentoforalamphotericinbtotreatsystemicfungalandparasiticinfectionshasthemythbeenfinallyrealized
_version_ 1725215717562777600

Similar Items